News & Updates
Filter by Specialty:

ALLEGRO-LT shows long-term benefit of ritlecitinib for alopecia areata
21 Sep 2022
byAudrey Abella
In the interim analysis of the ongoing phase III ALLEGRO-LT trial, the investigational oral JAK3*/TEC inhibitor ritlecitinib demonstrated long-term safety and remarkable scalp hair regrowth in adults and adolescents with alopecia areata (AA).